About albutrepe nonacog alfa
Long-acting clotting factor IX replacement
Used for
- Preventing bleeding in haemophilia B
- Treating bleeding episodes in haemophilia B
- Preventing bleeding during surgery in haemophilia B
Usual adult dose
Prevention: 25–50 IU/kg intravenously weekly; selected patients use longer intervals. Bleeding and surgery doses depend on severity and factor IX levels.
Usual dose in children
Under 12 years: usually 40–55 IU/kg intravenously weekly for prevention. Older children generally follow adult schedules; bleeding doses vary.
Common side effects
- Headache
- Dizziness
- Rash
- Injection-site reactions
Important warnings
- Severe allergic reactions, including anaphylaxis, can occur
- Antibodies may develop and reduce treatment effectiveness
- Blood clots can occur, particularly in higher-risk patients
- Factor IX monitoring is needed, especially during surgery
Pregnancy
Pregnancy data are limited. Use requires assessment of expected benefits and potential risks.
Breastfeeding
Whether it passes into breast milk is unknown. Effects on breastfed infants have not been established.
Interactions
- No established medicine interactions
- Do not mix with other medicines in the same syringe
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.